Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KTTA | US
0.07
1.62%
Healthcare
Biotechnology
30/06/2024
21/10/2024
4.39
4.35
4.48
4.22
Pasithea Therapeutics Corp. a biotechnology company engages in research and discovery of treatments for Central Nervous System disorders RASopathies and other diseases. It operates through two segments Therapeutics and Clinics. The company provides business support services to anti-depression clinics entities and registered healthcare providers. Its lead product candidate PAS-004 a next-generation mitogen-activated protein kinase or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies including neurofibromatosis type 1 and Noonan syndrome as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003 to treat amyotrophic lateral sclerosis; PAS-002 for the treatment multiple sclerosis; and PAS-001 to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach Florida.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
104.3%1 month
219.4%3 months
162.8%6 months
124.4%-
-
0.28
-
-
2.90
277.44
-
-16.27M
4.59M
4.59M
-
-
-
1.50K
-63.25
0.06
20.78
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.52
Range1M
3.70
Range3M
3.89
Rel. volume
0.01
Price X volume
111.68K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Molecular Templates Inc | MTEM | Biotechnology | 0.75 | 4.94M | 0.00% | n/a | 155.07% |
QLGN | QLGN | Biotechnology | 0.1825 | 4.93M | 9.15% | n/a | -39.04% |
Enveric Biosciences Inc | ENVB | Biotechnology | 0.538 | 4.80M | 20.33% | n/a | 0.00% |
CNS PHARMACEUTICALS INC | CNSP | Biotechnology | 0.146 | 4.69M | 19.67% | n/a | -2.87% |
Azitra Inc | AZTR | Biotechnology | 0.61 | 4.65M | 0.00% | 0.01 | 41.86% |
ADTX | ADTX | Biotechnology | 1.09 | 4.60M | 3.81% | n/a | 122.46% |
Hepion Pharmaceuticals Inc | HEPA | Biotechnology | 0.7501 | 4.35M | -8.30% | n/a | 4.33% |
AquaBounty Technologies Inc | AQB | Biotechnology | 1.1 | 4.25M | -8.33% | n/a | 10.41% |
Titan Pharmaceuticals Inc | TTNP | Biotechnology | 4.58 | 4.19M | -4.38% | n/a | 0.00% |
NuCana plc | NCNA | Biotechnology | 1.86 | 4.18M | -1.06% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 2.90 | 0.53 | Expensive |
Ent. to Revenue | 277.44 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 0.28 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 162.76 | 72.80 | Riskier |
Debt to Equity | - | -1.23 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 4.59M | 3.66B | Emerging |